{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=leronlimab+%28PRO+140%29",
    "query": {
      "intervention": "leronlimab (PRO 140)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 24,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=leronlimab+%28PRO+140%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T20:24:47.824Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02175680",
      "title": "Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV",
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "PRO 140",
          "type": "DRUG"
        },
        {
          "name": "Historical data",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-04-16",
      "completion_date": "2015-02-02",
      "has_results": true,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-09-25T20:24:47.824Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02175680"
    },
    {
      "nct_id": "NCT04347239",
      "title": "Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus Disease 2019"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Leronlimab (700mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 484,
      "start_date": "2020-04-16",
      "completion_date": "2022-06-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-09-25T20:24:47.824Z",
      "location_count": 18,
      "location_summary": "Alexander City, Alabama • Fullerton, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04347239"
    },
    {
      "nct_id": "NCT04504942",
      "title": "Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "Leronlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2020-05-01",
      "completion_date": "2025-01-27",
      "has_results": true,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-09-25T20:24:47.824Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04504942"
    },
    {
      "nct_id": "NCT02438345",
      "title": "PRO 140 for Human Immunodeficiency Virus",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "PRO 140",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Drexel University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-11",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-09-25T20:24:47.824Z",
      "location_count": 1,
      "location_summary": "Phildadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Phildadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02438345"
    },
    {
      "nct_id": "NCT00110591",
      "title": "Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "PRO 140",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2004-04-16",
      "completion_date": "2008-03-31",
      "has_results": true,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-09-25T20:24:47.824Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110591"
    },
    {
      "nct_id": "NCT02355184",
      "title": "An Extension of Protocol PRO 140_CD01 Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV",
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "PRO 140 350mg weekly subcutaneous (SC) injection.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2014-11-18",
      "completion_date": "2022-07-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-07",
      "last_synced_at": "2026-09-25T20:24:47.824Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02355184"
    },
    {
      "nct_id": "NCT07553338",
      "title": "Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease",
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Leronlimab (700mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-04-30",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-09-25T20:24:47.824Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07553338"
    },
    {
      "nct_id": "NCT04521114",
      "title": "Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "leronlimab 700 mg",
          "type": "DRUG"
        },
        {
          "name": "leronlimab 350 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 87,
      "start_date": "2020-12-01",
      "completion_date": "2021-12-29",
      "has_results": true,
      "last_update_posted_date": "2023-03-01",
      "last_synced_at": "2026-09-25T20:24:47.824Z",
      "location_count": 7,
      "location_summary": "Coronado, California • Maitland, Florida • Miami Lakes, Florida + 4 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Ocoee",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04521114"
    },
    {
      "nct_id": "NCT02859961",
      "title": "Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "PRO 140 (350 mg)",
          "type": "DRUG"
        },
        {
          "name": "PRO 140 (525 mg)",
          "type": "DRUG"
        },
        {
          "name": "PRO 140 (700 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 562,
      "start_date": "2016-12-07",
      "completion_date": "2020-12-07",
      "has_results": true,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-09-25T20:24:47.824Z",
      "location_count": 12,
      "location_summary": "La Mesa, California • Palm Springs, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859961"
    },
    {
      "nct_id": "NCT07536815",
      "title": "An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "TNBC",
        "TNBC - Triple-Negative Breast Cancer",
        "TNBC, Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "leronlimab (PRO 140)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-09-25T20:24:47.824Z",
      "location_count": 1,
      "location_summary": "Salem, Oregon",
      "locations": [
        {
          "city": "Salem",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07536815"
    }
  ]
}